deferiprone has been researched along with Mucormycosis in 3 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Mucormycosis: Infection in humans and animals caused by any fungus in the order MUCORALES (e.g., RHIZOPUS; MUCOR; CUNNINGHAMELLA; APOPHYSOMYCES; ABSIDIA; SAKSENAEA and RHIZOMUCOR) There are many clinical types associated with infection including central nervous system, lung, gastrointestinal tract, skin, orbit and paranasal sinuses. In humans, it usually occurs as an OPPORTUNISTIC INFECTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In addition, we compared the efficacy of deferiprone with that of liposomal amphotericin B (LAmB) in treating mucormycosis in diabetic ketoacidotic mice." | 7.73 | Deferiprone iron chelation as a novel therapy for experimental mucormycosis. ( Edwards, JE; Fu, Y; Ibrahim, AS; Spellberg, B, 2006) |
| "The increased risk of mucormycosis in patients with renal failure receiving deferoxamine iron chelation therapy is explained by the fact that deferoxamine actually acts as a siderophore for the agents of mucormycosis, supplying previously unavailable iron to the fungi." | 4.84 | Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. ( Edwards, J; Ibrahim, AS; Spellberg, B, 2008) |
| " In addition, we compared the efficacy of deferiprone with that of liposomal amphotericin B (LAmB) in treating mucormycosis in diabetic ketoacidotic mice." | 3.73 | Deferiprone iron chelation as a novel therapy for experimental mucormycosis. ( Edwards, JE; Fu, Y; Ibrahim, AS; Spellberg, B, 2006) |
| "Deferoxamine (DFO), when used in dialysis patients, is a well recognized risk factor for the development of mucormycosis caused by Rhizopus." | 3.69 | Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. ( Boelaert, JR; Crichton, RR; de Locht, M; Schneider, YJ; Van Cutsem, J, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ibrahim, AS | 2 |
| Spellberg, B | 2 |
| Edwards, J | 1 |
| Edwards, JE | 1 |
| Fu, Y | 1 |
| Boelaert, JR | 1 |
| Van Cutsem, J | 1 |
| de Locht, M | 1 |
| Schneider, YJ | 1 |
| Crichton, RR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study[NCT00419770] | Phase 2 | 20 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00419770)
Timeframe: 30 Days After End of Therapy
| Intervention | Events (Number) |
|---|---|
| Deferasirox | 16 |
| Placebo | 16 |
1 review available for deferiprone and Mucormycosis
| Article | Year |
|---|---|
Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment.
Topics: Animals; Benzoates; Chelating Agents; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Microbia | 2008 |
2 other studies available for deferiprone and Mucormycosis
| Article | Year |
|---|---|
Deferiprone iron chelation as a novel therapy for experimental mucormycosis.
Topics: Amphotericin B; Animals; Antifungal Agents; Deferiprone; Diabetic Ketoacidosis; Humans; Iron Chelati | 2006 |
Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect.
Topics: Animals; Deferiprone; Deferoxamine; Guinea Pigs; Iron; Iron Chelating Agents; Male; Mucormycosis; Py | 1994 |